Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04863950 · ClinicalTrials.gov registry record · Phase 2
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04863950: Recruiting Phase 2 study of Glioblastoma, sponsored by The University of Texas Health Science Center at San Antonio.
NCT04863950 is a Phase 2 study of Glioblastoma that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 25 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04863950, a Phase 2 study of Glioblastoma, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
Conditions Studied
Interventions
- DRUG Lomustine
- DRUG Imipramine Hydrochloride
Study Locations (1)
Texas
- Mays Cancer Center, UT Health San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What NCT04863950 shows while recruiting
NCT04863950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Lomustine is the first listed.
NCT04863950 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04863950 about?
NCT04863950 is a clinical study titled "Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma". This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
What is the current status of trial NCT04863950?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2022-05-25. Estimated completion is 2026-11.
What conditions does trial NCT04863950 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04863950?
The interventions under investigation include: Lomustine (DRUG), Imipramine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04863950?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04863950 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04863950's enrollment target sits among peer trials
25 138th of 199 higher than 60 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI